THOMAS FRANK E
SEC Form 4 insider trading activity
THOMAS FRANK E has filed 2 SEC Form 4 filings (2 transaction rows) across 2 companies, including SPRO, LRMR, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 25, 2026.
On the most recent filing, THOMAS FRANK E is listed as Director at Larimar Therapeutics, Inc. Inside the rolling window, THOMAS FRANK E reported 1 open-market purchase totaling $25K in LRMR and no open-market sales.
Companies traded
Other insiders at SPRO
Insider Buying
$25K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has THOMAS FRANK E made?
THOMAS FRANK E has filed 2 SEC Form 4 filings (2 transaction rows) across 2 companies, including SPRO, LRMR since 2026.
Which companies does THOMAS FRANK E trade?
THOMAS FRANK E has filed SEC Form 4 disclosures for 2 companies, including SPRO, LRMR.
When was THOMAS FRANK E's most recent SEC Form 4 filing?
THOMAS FRANK E's most recent SEC Form 4 filing on Tracefour is dated Jun 25, 2026.
What is THOMAS FRANK E's total buy and sell value in the current window?
Inside the rolling retention window, THOMAS FRANK E bought $25K and sold $0 based on SEC Form 4 filings.
What was THOMAS FRANK E's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 5,000 LRMR shares on 2026-02-27, worth $25K, per SEC Form 4 filings.